The Role of Human Cytochrome P450 Enzymes in the Formation of 2-Hydroxymetronidazole: CYP2A6 is the High Affinity (Low K_m) Catalyst

Abstract

Despite metronidazole's widespread clinical use since the 1960s, the specific enzymes involved in its biotransformation have not been previously identified. Hence, in vitro studies were conducted to identify and characterize the cytochrome P450 enzymes involved in the formation of the major metabolite, 2-hydroxymetronidazole. Formation of 2-hydroxymetronidazole in human liver microsomes was consistent with biphasic, Michaelis-Menten kinetics. Although several cDNA-expressed P450 enzymes catalyzed 2-hydroxymetronidazole formation at a supratherapeutic concentration of metronidazole (2000 mM), at a "therapeutic concentration" of 100 mM only CYPs 2A6, 3A4, 3A5, and 3A7 catalyzed metronidazole 2-hydroxylation at rates substantially greater than control vector, and CYP2A6 catalyzed 2-hydroxymetronidazole formation at rates 6-fold higher than the next most active enzyme. Kinetic studies with these recombinant enzymes revealed that CYP2A6 has a K m = 289 mM which is comparable to the K m for the high-affinity (low-K m ) enzyme in human liver microsomes, whereas the K m values for the CYP3A enzymes corresponded with the low-affinity (high-K m ) component. The sample-to-sample variation in 2-hydroxymetronidazole formation correlated significantly with CYP2A6 activity (r ‡ 0.970, P < 0.001) at substrate concentrations of 100 and 300 mM. Selective chemical inhibitors of CYP2A6 inhibited metronidazole 2-hydroxylation in a concentration-dependent manner and inhibitory antibodies against CYP2A6 virtually eliminated metronidazole 2-hydroxylation (>99%). Chemical and antibody inhibitors of other P450 enzymes had little or no effect on metronidazole 2-hydroxylation. These results suggest that CYP2A6 is the primary catalyst responsible for the 2-hydroxylation of metronidazole, a reaction that may function as a marker of CYP2A6 activity both in vitro and in vivo.

Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: Model-based evaluation of standard dosing regimens

“…Saturable processes have been described to be involved in the elimination of both drugs [16,17]. Michaelis-Menten kinetics were used to code the saturable processes.…”

Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review

“…Metronidazole is metabolized in the liver to 2-hydroxymetronidazole by CYP2A6, and to a lesser extent by CYP3A4, CYP3A5 and CYP3A7 (Table 2) [125]. Metronidazole is an inhibitor of CYP2C9, and possibly inhibits CYP3A4 [121] but not P-gp in humans [126].…”

The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans

“…The major metabolite of MET was 2-hydroxyMET formed by M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 16 oxidation of the side chain in the C-2 position of the imidazole ring, which was mainly mediated by CYP2A6 [28]. PAN was metabolized extensively in vivo, and its phase I metabolic reactions mainly included sulfoxide oxidation and reduction (mainly catalyzed by CYP3A4), 4'-O-demethylation and aromatic hydroxylation (catalyzed by CYP2C19 and CYP3A4).…”